

31 January 2014

ASX ANNOUNCEMENT

APPENDIX 4C - QUARTERLY CASH FLOW

Analytica Limited (the Company) presents its Appendix 4C for the quarter ended 31st December 2013.

Thanks to the strong support of our shareholders, directors and underwriter (Patersons Securities), Analytica's successfully raised \$2,200k in October 2013 via an underwritten share purchase plan (Patersons Securities - \$1.8m) and a placement with directors (\$400k).

This fundraising strengthens the ability of Analytica to maintain the momentum of the rollout of the PeriCoach and continue to meet the milestones for market launch in May 2014. The PeriCoach System is a medical device intended for use by women with incontinence problems. Approximately one third of all women have some level of incontinence.

In November successful registration of the PeriCoach was received from the Therapeutic Goods Administration (TGA). Inclusion on the Australian Register of Therapeutic Goods (ARTG) allows the PeriCoach system to be marketed in Australia. Analytica will initially use the registration to supply a limited number of devices for controlled field trials. These trials are currently underway and on schedule, providing 'real world' useability tests with an opportunity to enhance the product before mass production.

Submission for registration of the PeriCoach for the European and United States market is close to completion and is on schedule.

On the 13th January 2014, Analytica strengthened the Board skills with the appointment of life sciences industry veteran Carl Stubbings as a nonexecutive director. Carl brings a wealth of experience and skills in international marketing, strategic planning and commercialisation. Mr Stubbings' experience in the sector spans over 30 years with a focus on medical diagnostics as well as biotechnology, with a particular emphasis on marketing across North America, Latin America, Asia Pacific and Europe as well as roles covering manufacturing and administration.

Research and development expenditure (\$579k), staff costs (\$38k), marketing expenses (\$53k) and fundraising costs (\$158k) accounted for the bulk of the operating cash flows for the quarter. With a continued tight control on expenditure, the cash balance at the end of the December quarter was \$1,425k.

CONTACT

Michael Monsour (Chairman)
Analytica Limited
(07) 3278 1950
mmonsour@analyticamedical.com

Rudi Michelson
Monsoon Communications
(03) 9620 3333
rudim@monsoon.com.au

About Analytica Limited

Analytica's lead product is the PeriCoach™ System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach™ comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is correctly performing pelvic floor exercises and if these are improving her condition; otherwise physicians are guided on the need for surgery.

PeriCoach™ has been approved in Australia with product launches expected in 2014 in Australia, Europe and the US. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.

Analytica is also commercialising the AutoStart™ Infusion System. This is a burette with improved safety and cost reduction features. It is targeting a \$3 billion pa global market, has FDA approval and potential near term cash flow with distribution agreements.



Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

31 December 2013

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (6 months) \$A'000
1.1 Receipts from customers		
1.2 Payments for		
(a) staff costs	(38)	(55)
(b) advertising and marketing	(53)	(87)
(c) research and development	(579)	(1104)
(d) leased assets	-	-
(e) other working capital	(401)	(400)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	7	7
1.5 Interest and other costs of finance paid	(2)	(3)
1.6 Income taxes paid	-	-
1.7 Other-		
(a) Net sales income	-	-
(b) R & D Tax Concession	521	521
(c) Royalty Income	-	1
Net operating cash flows	(545)	(1120)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

		Current quarter \$A'000	Year to date (6 months) \$A'000
1.8	Net operating cash flows (carried forward)	(545)	(1120)
	Cash flows related to investing activities		
1.9	Payment for acquisition of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(2)	(4)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (purchase of Convertible Notes)	-	-
	Net investing cash flows	(2)	(4)
1.14	Total operating and investing cash flows	(547)	(1124)
	Cash flows related to financing activities		
1.15	Proceeds from issues of shares	2200	2200
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	213
1.18	Repayment of borrowings:	(213)	(213)
1.19	Dividends paid	-	-
1.20	Other Creditors (costs of fund raising)	-	-
	Net financing cash flows	1987	2200
	Net increase (decrease) in cash held	1440	1076
1.21	Cash at beginning of quarter/year to date	(15)	349
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	Cash at end of quarter	1425	1425

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	48
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Payment of director's fees and compulsory superannuation.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	400	0
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1425	-
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	(15)
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	1425	(15)

Acquisitions and disposals of business entities

	Acquisitions	Disposals
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: original signed

Date: 30th January 2014

Print name: Ross Managlesdorf

+ See chapter 19 for defined terms.